Literature DB >> 28447276

Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab.

R Quintavalla1, M Lombardi1, P Prandoni2, C Manotti3, I Tadonio4, F Re5, P M Ferrini1, M I Tassoni1, P Rossetti1, F Quaini6.   

Abstract

Entities:  

Keywords:  Cerebral hemorrhage; Dabigatran; Ibrutinib; Idarucizumab

Year:  2017        PMID： 28447276     DOI： 10.1007/s40520-017-0752-5

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN： 1594-0667            Impact factor:   3.636


× No keyword cloud information.
  4 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Authors:  Markus C Stühlinger; Ansgar Weltermann; Philipp Staber; Daniel Heintel; Thomas Nösslinger; Michael Steurer
Journal:  Wien Klin Wochenschr       Date:  2019-08-14       Impact factor: 1.704

3.  Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series.

Authors:  Senta Frol; Dimitrios Sagris; Mišo Šabovič; George Ntaios; Janja Pretnar Oblak
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

Review 4.  The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.

Authors:  Milo Gatti; Emanuel Raschi; Elisabetta Poluzzi; Cristian Martignani; Stefania Salvagni; Andrea Ardizzoni; Igor Diemberger
Journal:  Curr Heart Fail Rep       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.